Pfizer Assembling New Commercial Team For Move Into Dermatology

The big pharma is moving into a new therapy area – dermatology – as part of a three-pronged strategy in Inflammation & Immunology that also includes rheumatology and gastroenterology. Pfizer’s first product for dermatology, crisaborole for atopic dermatitis, could launch next year.

Pfizer Inc. is building a specialized dermatology sales force as it moves into the therapy area as part of a broader strategy in inflammation and immunology. The company could launch its first drug in dermatology – crisaborole for atopic dermatitis – early next year, and Pfizer expects the drug to anchor a dermatology franchise.

Crisaborole, which Pfizer acquired earlier this year with the acquisition of Anacor Pharmaceuticals Inc. for $5.2bn, is pending approval...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Dermatological

More from Therapy Areas

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By 

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.